🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Newcastle upon Tyne
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Newcastle upon Tyne

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 19 Sep 2026, 04:26 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 2003 Manchester 674 Birmingham 469 Glasgow 437 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca18 Hoffmann-La Roche14 Janssen Research & Development, LLC12 Novartis Pharmaceuticals11 Merck Sharp & Dohme LLC10
Site city
London2003 Manchester674 Birmingham469 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
251 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
NCT07107945Chronic Kidney Disease
Boehringer Ingelheim
Phase 3
120
Birmingham, Bristol, Glasgow, Liverpool, London, Newcastle upon Tyne, Nottingham, Southampton
2025-12-09
Recruiting
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
NCT07137598Rheumatoid Arthritis
Hoffmann-La Roche
Phase 2
160
Leicester, Doncaster, Newcastle upon Tyne, Barnet
2025-12-05
Recruiting
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
NCT07116031Chronic Graft Versus Host Disease
Sanofi
Phase 2
37
Newcastle upon Tyne, London
2025-12-02
Recruiting
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
NCT07161414Advanced Solid Tumors
AstraZeneca
Phase 1
40
Newcastle upon Tyne, Sutton
2025-11-25
Recruiting
TrueLok Elevate PMCF Study
NCT07079774Wound of Skin, Ulcers, Soft Tissue Defect
Orthofix s.r.l.
Observational
153
Hull, Newcastle upon Tyne
2025-11-24
Active, closed
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vertex Pharmaceuticals Incorporated
Phase 2
26
Birmingham, London, Newcastle upon Tyne, Sheffield
2025-11-19
Recruiting
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07188805Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Bayer
Phase 3
111
Leicester, Liverpool, Belfast, Glasgow, Newcastle upon Tyne, Leeds, Bristol
2025-11-19
Recruiting
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
NCT07186842Advanced Solid Cancers
BioNTech SE
Phase 1/2
245
Leeds, London, Manchester, Newcastle upon Tyne, Sutton
2025-11-18
Recruiting
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
NCT07215585Large B-cell Lymphoma
AstraZeneca
Phase 3
420
Glasgow, Scotland, London, Newcastle upon Tyne, Nottingham
2025-11-11
Recruiting
Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
NCT07123155Pompe Disease
Shionogi
Phase 2
45
Birmingham, London, Newcastle upon Tyne, Salford
2025-10-30
Recruiting
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
NCT07217067Atrial Fibrillation
Novartis Pharmaceuticals
Phase 2
165
Brighton, Newcastle upon Tyne, Liverpool, London
2025-10-28
Recruiting
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
NCT07266805Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
Pharvaris Netherlands B.V.
Phase 3
32
Bristol, Cambridge, Leicester, London, Newcastle upon Tyne, Plymouth
2025-10-16
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company
Phase 3
4,500
Aberdeen, Clifton, Enfield, Glasgow, Ipswich, Liverpool, London, Newcastle upon Tyne
2025-10-15
Active, closed
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
NCT07033481Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
EIP Pharma Inc
Phase 2
20
Cambridge, Newcastle upon Tyne
2025-10-02
Recruiting
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07123454B-cell Non-Hodgkin Lymphoma
AstraZeneca
Phase 1/2
91
London, Newcastle upon Tyne
2025-09-24
Recruiting
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
NCT07053423Chronic Obstructive Pulmonary Disease
Sanofi
Phase 4
218
Newcastle upon Tyne, Southampton, Leicester, Bradford
2025-09-22
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520Non-small Cell Lung Cancer
BioNTech SE
Phase 1/2
880
London, Newcastle upon Tyne, Sutton
2025-09-22
Recruiting
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
NCT07013201Palmoplantar Pustulosis
LEO Pharma
Phase 2
135
Bristol, London, Newcastle upon Tyne, Salford, Stourbridge
2025-09-11
Recruiting
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771Carcinoma, Non-Small-Cell Lung
Bristol-Myers Squibb
Phase 2
182
Birmingham, London, Newcastle upon Tyne
2025-09-09
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.
Phase 3
720
Cambridge, Cottingham, Exeter, Glasgow, Leeds, London, Manchester, Newcastle upon Tyne
2025-09-08
Recruiting
A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease
NCT06984627Graves' Disease
Sanofi
Phase 2
30
Milton Keynes, Newcastle upon Tyne
2025-09-02
Recruiting
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)
ADARx Pharmaceuticals, Inc.
Phase 2
45
Leicester, Newcastle upon Tyne
2025-08-28
Recruiting
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
NCT07151040Solid Tumor, Colorectal Cancer (CRC), Squamous Cell Carcinoma of Head and Neck, Non-Small Cell Lung Cancer (NSCLC)
One-carbon Therapeutics AB
Phase 1/2
43
Newcastle upon Tyne
2025-08-22
Active, closed
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
NCT06961344Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Tisento Therapeutics
Phase 2
44
London, Newcastle upon Tyne
2025-08-18
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232Advanced Solid Tumor
BioNTech SE
Phase 1/2
1,438
Birmingham, Cardiff, Glasgow, Liverpool, London, Manchester, Newcastle upon Tyne, Southampton
2025-08-12
Rows per page Showing 26–50 of 251
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-uk/city/newcastle-upon-tyne

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.